MA43389A - ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE - Google Patents

ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE

Info

Publication number
MA43389A
MA43389A MA043389A MA43389A MA43389A MA 43389 A MA43389 A MA 43389A MA 043389 A MA043389 A MA 043389A MA 43389 A MA43389 A MA 43389A MA 43389 A MA43389 A MA 43389A
Authority
MA
Morocco
Prior art keywords
antibodies
processes
Prior art date
Application number
MA043389A
Other languages
French (fr)
Inventor
Ekaterina V Breous-Nystrom
Daniel Hirschhorn-Cymerman
Taha Merghoub
Gerd Ritter
David Schaer
Volker Seibert
Dijk Marc Van
Jeremy D Waight
Nicholas S Wilson
Original Assignee
Agenus Inc
Ludwig Inst For Cancer Res Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc, Ludwig Inst For Cancer Res Ltd, Memorial Sloan Kettering Cancer Center filed Critical Agenus Inc
Publication of MA43389A publication Critical patent/MA43389A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043389A 2015-12-02 2016-12-02 ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE MA43389A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562262371P 2015-12-02 2015-12-02

Publications (1)

Publication Number Publication Date
MA43389A true MA43389A (en) 2021-05-12

Family

ID=58797926

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043389A MA43389A (en) 2015-12-02 2016-12-02 ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE

Country Status (3)

Country Link
EP (1) EP3383914A4 (en)
MA (1) MA43389A (en)
WO (1) WO2017096281A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014188A (en) 2015-05-07 2018-04-10 Agenus Inc Anti-ox40 antibodies and methods of use thereof.
JP7089470B2 (en) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド Antibodies and how to use them
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
HUE050399T2 (en) 2016-12-15 2020-12-28 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
JP2021501801A (en) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Immunostimulatory agonist antibody for use in the treatment of cancer
BR112020018539A2 (en) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company ANTIBODIES AGAINST MICA AND / OR MICB AND USES OF THE SAME
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
CA3103040A1 (en) * 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
CN112368052A (en) 2018-07-03 2021-02-12 吉利德科学公司 Antibodies targeting HIV GP120 and methods of use
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CA3115680A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
WO2020142626A1 (en) * 2019-01-04 2020-07-09 Gigagen, Inc. Anti-ox40 binding proteins and methods of use thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
TW202231277A (en) 2019-05-21 2022-08-16 美商基利科學股份有限公司 Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
CN114245869A (en) 2019-05-23 2022-03-25 百时美施贵宝公司 Method for monitoring cell culture medium
JP2022534982A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and their uses
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CR20210687A (en) 2019-06-25 2022-03-03 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
JP7398556B2 (en) 2019-09-30 2023-12-14 ギリアード サイエンシーズ， インコーポレイテッド HBV vaccine and methods of treating HBV
MX2022004370A (en) 2019-10-18 2022-05-06 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia.
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (en) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1 inhibitors
CN116057068A (en) 2019-12-06 2023-05-02 精密生物科学公司 Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes
MX2022007930A (en) 2019-12-24 2022-08-08 Carna Biosciences Inc Diacylglycerol kinase modulating compounds.
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
CN115605493A (en) 2020-03-20 2023-01-13 吉利德科学公司（Us） Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
US20220119426A1 (en) 2020-08-07 2022-04-21 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
CN114106173A (en) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 anti-OX 40 antibodies, pharmaceutical compositions and uses thereof
BR112023003553A2 (en) 2020-08-31 2023-04-04 Bristol Myers Squibb Co CELLULAR LOCATION AND IMMUNOTHERAPY SIGNATURE
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
MX2023007734A (en) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Antibody compositions and methods of use thereof.
MX2023007650A (en) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Subcutaneous administration of pd1/pd-l1 antibodies.
CA3206883A1 (en) 2020-12-31 2022-07-07 Sanofi Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
KR20240006683A (en) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 Combination of TLR8 modulating compounds and anti-HBV siRNA therapeutics
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (en) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3238270A1 (en) 2021-12-03 2023-06-08 Gediminas J. Brizgys Therapeutic compounds for hiv virus infection
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
TW202346277A (en) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros zinc finger family degraders and uses thereof
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
TW202400172A (en) 2022-04-06 2024-01-01 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
TW202402280A (en) 2022-07-01 2024-01-16 美商基利科學股份有限公司 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2009030237A2 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
EA201201435A1 (en) * 2010-04-20 2013-04-30 Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
BR112013004266A8 (en) * 2010-08-23 2018-01-02 Univ Texas anti-ox40 antibodies and methods of use.
BR112016013963A2 (en) * 2013-12-17 2017-10-10 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Also Published As

Publication number Publication date
EP3383914A1 (en) 2018-10-10
WO2017096281A1 (en) 2017-06-08
EP3383914A4 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
MA43389A (en) ANTI-OX40 ANTIBODIES AND PROCESSES FOR USE
MA46529A (en) ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
MA46770A (en) ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
MA50949A (en) ANTI-CTLA-4 ANTIBODIES AND PROCESSES FOR USE
MA42447A (en) ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
MA49950A (en) ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE
MA42971A (en) ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA53355A (en) ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
MA42043A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF
MA47691A (en) ANTI-CD33 ANTIBODIES AND PROCESSES FOR USE
MA51552A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
MA43018A (en) ANTI-PD1 ANTIBODIES AND METHODS OF USE
MA43365A (en) ANTI-DR5 ANTIBODIES AND METHODS FOR USING THE SAME
MA47849A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA43827A (en) CYCLIC DI-NUCLEOTID COMPOUNDS AND PROCESSES FOR USE
MA43658A (en) ANTI-MMR1 ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USE THEREOF
MA44524A (en) NEOANTIGENS AND THEIR METHODS OF USE
MA41558A (en) MIXED ALLERGEN COMPOSITIONS AND PROCESSES FOR USE
MA46708A (en) ANTI-PD1 ANTIBODIES AND THEIR USES
MA50948A (en) ANTIBODIES AND METHODS OF USING THE SAME
MA44081A (en) ANTI-C5 ANTIBODIES AND THEIR METHODS OF USE
MA55097A (en) OXYSTEROLS AND METHODS OF USE THEREOF
MA53184A (en) ANTI-OX40 ANTIBODIES AND THEIR USES
MA49537A (en) ANTI-LAG3 ANTIBODIES AND THEIR USES
MA45004A (en) ANTI-WT1-HLA SPECIFIC ANTIBODIES